Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides - Wikidata - awgldk - TriplyDB

Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides

Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides

http://www.wikidata.org/entity/Q36032748

about

The arsenal of pathogens and antivirulence therapeutic strategies for disarming them Perspective: Adhesion Mediated Signal Transduction in Bacterial Pathogens The tyrosine gate of the bacterial lectin FimH: a conformational analysis by NMR spectroscopy and X-ray crystallography The Antiadhesive Strategy in Crohn's Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut Inflammation-Induced Adhesin-Receptor Interaction Provides a Fitness Advantage to Uropathogenic E. coli during Chronic Infection Urinary Tract Infection: Pathogenesis and Outlook.Mutation of Tyr137 of the universal Escherichia coli fimbrial adhesin FimH relaxes the tyrosine gate prior to mannose binding.Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.Second generation of thiazolylmannosides, FimH antagonists for E. coli-induced Crohn's disease.Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.Targeting the bacteria-host interface: strategies in anti-adhesion therapy.Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections Binuclear copper(II) complexes discriminating epimeric glycosides and α- and β-glycosidic bonds in aqueous solution.New and alternative approaches to tackling antibiotic resistance.Use of tetravalent galabiose for inhibition of streptococcus suis serotype 2 infection in a mouse model Toward the Rational Design of Galactosylated Glycoclusters That Target Pseudomonas aeruginosa Lectin A (LecA): Influence of Linker Arms That Lead to Low-Nanomolar Multivalent Ligands.Effect of Aminophenyl and Aminothiahexyl α-D-Glycosides of the Manno-, Gluco-, and Galacto-Series on Type 1 Fimbriae-Mediated Adhesion of Escherichia coli.The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease.Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Anti-virulence Strategies to Target Bacterial Infections.Inhibition of type 1 fimbriae-mediated Escherichia coli adhesion and biofilm formation by trimeric cluster thiomannosides conjugated to diamond nanoparticles.Small Molecules That Sabotage Bacterial Virulence.Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action.Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies.Sites for Dynamic Protein-Carbohydrate Interactions of O- and C-Linked Mannosides on the E. coli FimH Adhesin.Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target?Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease.Conformational Switch of the Bacterial Adhesin FimH in the Absence of the Regulatory Domain - Engineering a Minimalistic Allosteric System.Virulence-targeted Antibacterials: Concept, Promise, and Susceptibility to Resistance Mechanisms.Physiochemical Tuning of Potent Escherichia coli Anti-Adhesives by Microencapsulation and Methylene Homologation.Glycan-functionalized diamond nanoparticles as potent E. coli anti-adhesives.Synthesis of branched-phosphodiester and mannose-centered fucosylated glycoclusters and their binding studies with Burkholderia ambifaria lectin (BambL)

P2860

Q26745604-D4DA9475-072F-4F8E-B6B2-5D971FD5F92D Q26768433-8EC4A321-F460-413C-BB0E-58F76B641601 Q27700666-1C662FE9-06A7-423C-B57E-207735AE6A67 Q27704226-7D2D258E-A772-4817-A61F-17B72B2C4D22 Q27728113-2924EA7C-4D5F-4C90-BE9E-6AFBFFFA417A Q30244953-EB168574-B278-41A8-BC19-08B6C805AE65 Q30399333-B26C3906-32E4-4172-B2B1-3AA7FD8C88D1 Q35809371-1D378016-C94D-423E-AC1E-19C8B4152CB9 Q35979422-253B43E5-85F2-460B-8340-A69CC6085265 Q36172411-0188E326-7203-49F5-9D3D-8F1E6B2C3B79 Q36760050-DAC83B54-1A69-456A-AC3E-06BA1C4A8D27 Q37009022-21C74916-2403-4103-9826-79F6C3A5A219 Q37147088-E8B9E5EF-B4CD-455B-83EC-B2838577DCC3 Q37230837-8A29853D-77D6-4DB2-8C44-52D6DBD80B48 Q37276605-20A8FB1A-C429-492F-BC0E-5211EC3A7053 Q37372123-9E08E78A-4D55-4ADD-9C22-085E83714DE0 Q37651483-A31FE6C5-3076-49FF-B062-6CA2A784B83B Q38291727-8291A1D5-1664-42F4-BC16-3F22794F422C Q38369339-1C3527FC-85B1-4B66-AEFF-F95FD54F1C2A Q38648792-0911906F-706B-4475-93B7-55C214583A2D Q38664310-F6AD3C3E-B863-4D03-A9D1-C07398E5A516 Q38760476-0DA6377B-0D9D-4FBE-8A3E-B6940D3ADAD1 Q38923171-9D5DC45E-6433-4F61-8B95-5C196DF5295C Q39139601-03F56EDC-6536-4A00-A379-F8B4448DFB9E Q39210862-8CA3FEEA-9D91-4973-B3AA-FDFC22A28AE7 Q39307431-1AB18FB4-140B-4641-AB12-A5FA9307559C Q40071513-B5D70BFC-D2AE-446D-B63C-1C357A5BFCE0 Q40149385-4E0916FE-6AC6-4129-8721-59891C337989 Q40172968-E74054EE-501B-46C7-AA49-9EF32E0EF867 Q40521114-442DE511-6653-422F-924F-DB21B1052AAD Q40749888-D6CA9524-2027-4296-A8F8-98CEF1F54ACA Q40906017-03CFF59F-C80B-48AB-96EA-6FC73CB86490 Q47309457-79AA84DB-6AB0-45D8-B117-A7DEED2223C5 Q48632952-66420A51-F6F8-4E46-9257-DDD54239BF03 Q51113098-2289782C-A055-43FB-AA5E-517841AA92F0 Q51832145-D1883666-36FE-4B42-A152-26F3303F9B40 Q56789085-6FCCEC17-023A-4EA3-87DC-BF9D096E48A3

P2860

Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides

http://www.wikidata.org/entity/Q36032748

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Lead optimization studies on F ...... ubstituted biphenyl mannosides

@ast

Lead optimization studies on F ...... ubstituted biphenyl mannosides

@en

type

label

Lead optimization studies on F ...... ubstituted biphenyl mannosides

@ast

Lead optimization studies on F ...... ubstituted biphenyl mannosides

@en

prefLabel

Lead optimization studies on F ...... ubstituted biphenyl mannosides

@ast

Lead optimization studies on F ...... ubstituted biphenyl mannosides

@en

P1433

Q36032748-88186544-39AC-4FAF-8CB9-F908E378EBD6

P1476

Q36032748-518BA92E-919B-4E42-A187-398E25769386

P2093

Q36032748-29AF0179-2E59-451A-B213-FEB0C164D8B3

Q36032748-49374739-5D3C-4B90-AD72-94D2A0FABA07

Q36032748-546DC5B5-3452-4FAD-AD3C-2C307C3A4E13

Q36032748-7F0C2DE7-272D-40DA-AB45-C1E84B7B62C0

Q36032748-A0568443-085A-4578-A9E6-CF67EC39DB54

Q36032748-A06CD66A-E05E-41FC-A22F-6002DFE92BD0

Q36032748-EA48A674-30E9-4F72-AEFE-6F5AE37071C6

Q36032748-FF21962F-5DCE-40CC-9D54-6FE015D6D545

P2860

Q36032748-02406951-CE99-43DD-85BD-E19DAA45ADE0

Q36032748-070DEB1E-270A-4E09-AD4F-88D354287B58

Q36032748-08874F95-6555-4163-8DF2-FCBF3223034A

Q36032748-1083CF02-DECB-487D-9ED5-A101C0E73886

Q36032748-11CB3E90-6925-4C7B-B922-8513D02858CC

Q36032748-184E03BD-83ED-4189-A9F4-645655E71F82

Q36032748-1863DDE7-E1B9-41B7-AE16-9DF13A735A3A

Q36032748-193C6949-7774-40C4-8357-5C61277E6E82

Q36032748-1F80CD13-13E4-4B2E-9787-39BE4802A7F9

Q36032748-227229FD-7F5B-437F-A499-4EF8873926BA

P304

Q36032748-EBB8DA8C-6D4C-4B9B-B500-A213C21C214F

P31

Q36032748-99B77620-31ED-4C12-85E7-E2E89E06EBA4

P356

Q36032748-69D64B52-F7F3-484D-A3FB-9DB4A7D44FAE

P407

Q36032748-350B136E-2306-4D7C-9576-35FD511507C9

P433

Q36032748-54A70FDA-1705-4740-AF8B-67667B79130B

P478

Q36032748-50289217-F7DA-47B3-BBED-35CEE40FA1F4

P50

Q36032748-7B329D3A-B2FC-4FB3-9FDC-A81717832F5D

Q36032748-8BEF5C4B-0544-4609-83FA-1AB1BAB95EC9

P577

Q36032748-58E4CDBE-4A9E-4AB2-8802-6E3C7C930CA5

P5875

Q36032748-6F0F99CD-E459-4C48-B9A0-BFE73B6222A7

P698

Q36032748-10FF7ED0-ACC7-431E-B3BE-833FC6F74FAC

P932

Q36032748-984A7DCA-3416-4389-B6B8-20A730AA7834

P356

P1433

Journal of Medicinal Chemistry

P1476

Lead optimization studies on F ...... ubstituted biphenyl mannosides

@en

P2093

Corinne K Cusumano

http://www.w3.org/2001/XMLSchema#string

Erik Chorell

http://www.w3.org/2001/XMLSchema#string

Jan M Crowley

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Henderson

http://www.w3.org/2001/XMLSchema#string

Jerome S Pinkner

http://www.w3.org/2001/XMLSchema#string

Scott Campbell

http://www.w3.org/2001/XMLSchema#string

Scott J Hultgren

http://www.w3.org/2001/XMLSchema#string

Zhenfu Han

http://www.w3.org/2001/XMLSchema#string

P2860

Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract

Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells

Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex

Uroplakins Ia and Ib, two major differentiation products of bladder epithelium, belong to a family of four transmembrane domain (4TM) proteins

Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination

The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

Differential stability and trade-off effects of pathoadaptive mutations in the Escherichia coli FimH adhesin

TLR4-mediated expulsion of bacteria from infected bladder epithelial cells.

P304

3945-3959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM300165M

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

James W. Janetka

P577

2012-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221980256

http://www.w3.org/2001/XMLSchema#string

P698

22449031

http://www.w3.org/2001/XMLSchema#string

P932

3375398

http://www.w3.org/2001/XMLSchema#string